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Background: Gamma-tocotrienol (GTT), an isomer of vitamin E and hydroxy-chavicol (HC), a major bioactive
compound in Piper betle, has been reported to possess anti-carcinogenic properties by modulating different
cellular signaling events. One possible strategy to overcome multi-drug resistance and high toxic doses of
treatment is by applying combinational therapy especially using natural bioactives in cancer treatment.
Methods: In this study, we investigated the interaction of GTT and HC and its mode of cell death on glioma
cell lines. GTT or HC alone and in combination were tested for cytotoxicity on glioma cell lines 1321N1 (Grade II),
SW1783 (Grade III) and LN18 (Grade IV) by [3-(4,5-dimethylthiazol-2- yl)-5-(3-carboxymethoxy-phenyl)-2-(4-sulfophenyl)-
2H- tetrazolium, inner salt] MTS assay. The interactions of each combination were evaluated by using the combination
index (CI) obtained from an isobologram.
Results: Individually, GTT or HC displayed mild growth inhibitory effects against glioma cancer cell lines at concentration
values ranging from 42–100 μg/ml and 75–119 μg/ml respectively. However, the combination of sub-lethal doses of
GTT + HC dramatically enhanced the inhibition of glioma cancer cell proliferation and exhibited a strong synergistic
effect on 1321N1 with CI of 0.55, and CI = 0.54 for SW1783. While in LN18 cells, moderate synergistic interaction of
GTT + HC was observed with CI value of 0.73. Exposure of grade II, III and IV cells to combined treatments for 24 hours
led to increased apoptosis as determined by annexin-V FITC/PI staining and caspase-3 apoptosis assay, showing
caspase-3 activation of 27%, 7.1% and 79% respectively.
Conclusion: In conclusion, combined treatments with sub-effective doses of GTT and HC resulted in synergistic
inhibition of cell proliferation through the induction of apoptosis of human glioma cells in vitro.
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Despite aggressive therapy attempts, mortality from malig-
nant astrocytic gliomas, the most common intrinsic brain
tumors in adults, still remains unacceptably high partly
due to chemo-resistance [1]. Patients with glioblastoma
multiforme (GBM) WHO grade IV have a poor prognosis
with a median overall survival of approximately 1 year
and fewer than 5% of patients will survive 5 years [2].
For anaplastic astrocytoma WHO grade III and its low-
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article, unless otherwise stated.median overall patients’ survival is typically 3 to 5 years
[3]. The use of alkylating substance such as temozolomide
(TMZ) in treating cancer patients is limited due to resist-
ance of tumor cells exhibiting increased activity of the
DNA repair enzyme O6-alkylguanine-DNA alkyltransfer-
ase [4]. Thus, the development of alternative therapeutic
strategies and to prevent recurrence is indicated.
Natural compounds with high effectiveness and fewer
side effects are desirable as substitutes for chemical
treatments which have various adverse effects. Alternative
therapeutic approaches such as the use of non-cytotoxic
dietary bioactives have potential for brain cancer because
many of these natural compounds possess pleiotropic
properties. To date, most mechanistic studies on chemo-Central Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly credited. The Creative Commons Public
mons.org/publicdomain/zero/1.0/) applies to the data made available in this
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fairly high concentrations which is unlikely to be achieved
by food intake [5]. Thus, combination of bioactives is
an alternative approach to uncover promising treatments
either as an adjuvant therapy or in the prevention of
recurrence, for cancer which are targeted and less toxic.
Before entering the clinical trial phase which is very
expensive, biomedical studies involving in vitro screening
and quantification of synergy is an approach to generate
fast, easy and robust data [6].
In this study, the concept of synergy interaction was
tested by analyzing the efficacy of gamma-tocotrienol
(GTT) and hydroxy-chavicol (HC) bioactives individually
and in combination against glioma cancer cell lines.
Tocotrienols possess more powerful anticancer, neuro-
protective and cholesterol-lowering properties that are
often not exhibited by tocopherols [7]. GTT, an isomer
of the vitamin E family from palm oil has been reported
to have anticancer activity and potent chemopreventive
effects on tumor cells. The effects of GTT have been
studied in colon and prostate cancer where GTT has
been found to modulate multiple signaling pathways
and induce apoptotic cell death [8]. Mechanisms involve
modulation of various signaling pathways including apop-
tosis by caspase-8 activation and mitochondrial depend-
ency, inhibition of cell proliferation, down-regulation of
cyclins, reduction in the Pl3K/PDK-1/Akt signaling and
NFκb activity and modulation of p53, Bax/Bcl2. Recently,
Yap and colleagues reported the modulation of ID family
proteins and mesenchymal markers in prostate and breast
cancer cells in response to GTT [9].
The deep green heart-shaped leaves commonly referred
to as “betel leaves” are traditionally consumed as a mouth
freshener in Eastern Asia. Hydroxy-chavicol (4-allyl-cat-
echol, 1-allyl-3,4-dihydroxybenzene, HC), a major phenolic
compound in Piper betle leaves which is frequently found
in a traditional Asian diet and remedies, has been shown to
induce cell apoptosis by the induction of oxidative stress,
glutathione (GSH) depletion and cell cycle deregulation
[10]. HC also exert its antitumor effects by enhancing the
immune response [11] and induce apoptosis by affecting
the mitochondrial signaling pathway and modulating
p53 [12]. Previous studies have suggested that HC exerts
antioxidant, anti-inflammatory [13], anti-nitrosation, anti-
mutagenic [14] and anti-carcinogenic properties against
various mutagens and carcinogens [10].
Synergism can be acquired if the element of bioactive
mixtures affect distinct targets or interact with one another
to improve the solubility and enhance the bioavailability
of one or several substances of the combined-compounds
in combination [15]. In theory, combination of compounds
can affect several targets, such as enzymes, substrates,
metabolites, receptors, ion channels, DNA/RNA, mono-
clonal antibodies, signal cascades and physicochemicalmechanisms [16]. Since these GTT and HC possess
their own unique activities, we investigate the nature of
interaction of these compounds by treating different
grades of glioma cells to a sub-effective dose of combined
GTT + HC, followed by the determination of cell prolif-
eration and apoptosis by the presence of caspase-3 and
annexin-V FITC/PI. We report the optimized combination




Gamma-tocotreinol (GTT) was purchased from Davos
Life Science Pte Ltd. (Singapore) and hydroxy-chavicol
(HC) from Hangzhou Imaginechem Co. Ltd. (Hangzhou,
China). FITC Active Caspase-3 Apoptosis Kit and FITC
Annexin V Apoptosis Detection Kit were purchased
from BD Biosciences (USA). Other chemicals used were
all of analytical grade.
Cell line and culture condition
Human glioblatoma cell lines 1321N1 were purchased
from the European Colection of Cell Culture (ECACC),
while SW1783 and LN18 were obtained from American
Type Culture Collection (ATCC) (Manassas, VA, USA).
1321N1 and LN18 were cultured in Dulbecco’s modified
Eagle medium (DMEM) supplemented with penicillin,
streptomycin, 10% fetal bovine serum (FBS) and 5% FBS
respectively in a humidified incubator at 37°C in an
atmosphere of 95% air and 5% CO2. SW1783 was main-
tained in Leibovitz, 10% FBS, in an atmosphere of 100%
air. Medium was changed three times a week, and cells
were passaged using accutase.
Treatments with natural compounds
Stock solutions of GTT and HC were prepared in absolute
ethanol and stored at −20°C. As vehicle, 0.1% of ethanol
was added to control cells.
Determination of cell viability
Viability of glioblastoma cancer cell lines treated with
four phytochemical compounds and their combinations
was assessed using CellTiter 96® Aqueous Non-Radioactive
Cell Proliferation Assay (Promega, USA) as previously
described. Briefly, cells were seeded in 96-well microtiter
plates (Nunc) at 1.0 × 104 per well. After 24 hour incuba-
tion, the medium was removed and the cells were treated
with 100 μl medium containing various concentrations
(50, 100, 150, 200 μg/ml) of GTT or HC compound
alone for 24 hours. After 24 hour incubation, the
medium was carefully removed, replaced with fresh
medium, 20 μl of [3-(4,5-dimethylthiazol-2- yl)-5-(3-car-
boxymethoxy-phenyl)-2-(4-sulfophenyl)- 2H- tetrazolium,
inner salt] (MTS) was added to each well and incubated
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at 490 nm in a VersaMax ELISA micro plate reader
(Molecular Device, USA). The percentage of viable
cells at each concentration was calculated by dividing
the absorbance (A490) of treated cells by that of control
cells. The half maximal inhibitory concentration (IC50)
was determined from the cell viability (%) vs. concentra-
tions graph. For bioactive compounds (GTT +HC) in
combination, ½ or ¼ of IC50 of GTT were initially titrated
to a range of concentrations (1, 10, 50, 100 μg/ml) of HC.
All assays were performed in triplicates and repeated in
three independent experiments.Active caspase-3 apoptosis assay
The presence of active caspase-3 using FITC Active
Caspase-3 Apoptosis Kit. Cells were plated in 60 mm
culture dish at a seeding density of 5 × 105 cells/dish.
GTT or HC was dissolved in ethanol, added to the culture
media to the specified final concentration. As vehicle,
0.1% of ethanol was added to control cells. Camptothecin
(CPT) was used as a positive control for apoptosis induc-
tion. After 24 h, cells were harvested and washed twice
with PBS. Assays were performed as described in the
manufacturer’s protocol. Briefly, cells were fixed in BD
Cytofix/Cytoperm solution, incubated in ice for 20 min,
washed with BD Perm/Wash buffer and FITC rabbit
anti-active caspase-3 antibody was added and incubated
for 30 min at room temperature. Fluorescence from
a population of 1 × 105 cells were detected using the
BD FACSCantoTM flow cytometer (Becton Dickenson,
Mountain View, CA, USA) and CellQuest Pro (IVD)
software (Becton Dickenson, Mountain View, CA, USA).
Assays were performed in duplicates and repeated in
three independent experiments.Annexin V-propidium iodide staining apoptosis assay
Apoptosis was determined using FITC Annexin V Apop-
tosis Detection Kit based on the membrane changes
(phosphatidylserin based). Cells were plated in 60 mm
culture dish at a seeding density of 5 × 105 cells/dish. GTT
or HC and GTT+HC in combination were dissolved in
ethanol, added to the culture media to the specified final
concentration. Vehicle was added alone to the culture
medium serving as the untreated control. The subsequent
procedures were carried out according to the instructions
provided by the manufacturer. Briefly, after 24 h, cells
were harvested, washed twice with PBS and resuspended
in 1X binding buffer. Annexin-V FITC and propidium
iodide (PI) were added and incubated for 15 min at
room temperature (25°C) in the dark. Fluorescence
from a population of 1 × 105 cells were detected using
the BD FACSCantoTM flow cytometer (Becton Dickenson,
Mountain View, CA, USA) and CellQuest Pro (IVD)software (Becton Dickenson, Mountain View, CA, USA).
The assays were done in duplicates and repeated in three
independent experiments.
Statistical analysis
The level of interaction between the two bioactives were
determined by isobologram analysis based on the Chou-
Talalay method [17,18] where the output is represented
as combination indexes (CI). The CI between two com-







Based on CI values, the extent of synergism/antagonism
was determined. In brief, CI values between 0.9 and 0.85
suggest a moderate synergy, whereas those in the range
of 0.7 to 0.3 are indicative of clear synergistic interactions
between the drugs. CI values in the range of 0.9 to 1.10
suggest a near additive effect.
Statistical analysis among the various treatment groups
in cell viability and apoptosis studies were performed by
SPSS 16.0 software using two-tailed Student’s t-test and
P < 0.05 were considered statistically significant. The data
were expressed as mean ± standard deviation (SD).
Results
Effect of GTT, HC and bioactives in combination on the
viability of glioma cells
Treatment with varying doses of GTT or HC on 1321N1,
SW1783 and LN18 cells showed that cytotoxicity induced
by GTT and HC was dose dependent with 90-95% inhib-
ition achieved at maximum concentration of 200 μg/ml
after 24 h of treatment (Figure 1(a) and (b)). Proliferation
of 1321N1 cells decreased when treated with GTT
resulting in a 50% reduction at 100 ± 10.22 μg/ml, while
SW1783 showed a significant decrease in proliferation
with 50% reduction at 79 ± 5.29 μg/ml, whereas the
inhibitory concentration at 50% cell death (IC50) values
of GTT for LN18 was 42 ± 2.52 μg/ml. The IC50 value
of HC for 1321N1 was 75 ± 7.51 μg/ml, while SW1783 cell
proliferation were 50% inhibited at IC50 of 95 ± 5.83 μg/
ml, while 50% of LN18 cell proliferation were inhibited at
119 ± 7.77 μg/ml (Table 1). Grade IV, LN18 cells are more
sensitive to GTT treatment alone compare to grade II
1321N1 and grade III SW1783 cell lines. However, grade
II 1321N1 cells are more susceptible to HC treatment
compared to other cell lines with a lower IC50 value.
Combined GTT +HC significantly inhibited the growth
of 1321N1, SW1783 and LN18 cells in a dose-dependent
manner (Figure 1(c)), where the growth inhibition of cells
affected by combined bioactives was found to be greater
than either compound alone at lower doses, yielding
combined IC50 values of 40 μg/ml of GTT + 12 μg/ml
Figure 1 Treatment of (a) gamma-tocotrienol (GTT), (b) hydroxyl-chavicol (HC) and (c) combination of GTT with HC; on 1321N1, SW1783
and LN18 for 24 h. The cell survival test was determined by MTS assay. Data is presented as means ± SD, n = 9. *P < 0.05 compare to untreated
1321N1; # P < 0.05 compare to untreated SW1783; $P < 0.05 compare to untreated LN18.
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Table 1 MTS cytotoxic effect of GTT and HC on human glioma cancer cells (1321N1, SW1783, LN18)
Cell lines Compound IC50 value (μg/ml) Viability (% cells)a
Grade II Gamma-tocotrienol (GTT) 100 ± 10.22 4.2 ± 1.34
1321N1 Hydroxy-chavicol (HC) 75 ± 7.51 5.2 ± 0.89
Grade III Gamma-tocotrienol (GTT) 79 ± 5.29 5.5 ± 2.48
SW1783 Hydroxy-chavicol (HC) 95 ± 5.83 10.5 ± 2.04
Grade II Gamma-tocotrienol (GTT) 42 ± 2.52 5.1 ± 1.82
LN18 Hydroxy-chavicol (HC) 119 ± 7.77 9.6 ± 1.66
aPercentage of cell viability after 24 h incubation of maximum concentration treatment (200 μg/ml) of each compound.
Viable cells (%) were expressed as the mean ± SD of three independent experiments.
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HC in SW1783 cells, and 20 μg/ml of GTT + 29 μg/ml
of HC in LN18 cell lines (Table 2). Moreover, combined
GTT+HC were noted to induce apoptotic morphological
changes such as membrane changes, condensation of
chromatin, vacuoles in the cytoplasmic membrane and
shrinkage of the cell size [19,20] in the glioma cells when
treated with IC50 doses by microscopic examination
(Figure 2a,b,c).
Analysis of interaction between combinations of compounds
The IC50 data obtained were plotted for analysis of
synergism by isobole diagram (Figure 3) and the com-
bination index (CI) was obtained. Analysis of the isobo-
logram and the interaction values revealed that all the
bioactive combinations showed synergism. Combined
sub-effective doses of GTT + HC enhanced the inhib-
ition of glioma cell proliferation and exhibited a strong
synergistic effect on 1321N1 and SW1783 with CI values
of 0.55 and 0.54 respectively. In LN18 cells, moderate
synergism interaction of GTT + HC was observed with
CI = 0.73 (Table 2).
The effect of combined GTT + HC bioactives on apoptosis
Characteristics of 1321N1, SW1783 and LN18 glioma cells
undergoing apoptosis while treated with combined bioac-
tives were determined by the presence of active caspase-3
and the staining of exposed phosphatidylserine on the
cell surface which is demonstrated during annexin-V
FITC/PI flow cytometry assay. A set of results from ActiveTable 2 The ratio of combined GTT and HC compounds at gro
SW1783, LN18 cells and combination index (CI) for each com
Type of cell line GTT:HC IC50a [μg/ml] GT
1321N1 10 : 3 12 10
SW1783 20 : 1 2 79
LN18 2 : 3 29 42
aIC50 of combined compounds.
bIC50 of individual compound.
cCI < 1.0 indicates synergism; 0.9 < CI < 1.10, near additive; CI > 1.10 indicates antago
The data are the average of three independent experiments.Caspase-3 Apoptosis assay and Annexin-V Apoptosis
assay were illustrated in Figures 4 and 5 respectively.
Treatment of combined GTT + HC on 1321N1 resulted
in 27.3% activation of caspase-3 compared to either
GTT (10.5%) or HC (3%) alone. There was only a slight
increase of active caspase-3 (7.1%) in SW1783 when
treated with combined GTT+HC compared to individual
compounds GTT (3%) or HC (2.5%). However, combined
GTT+HC treatment on LN18 resulted in 79.4% activa-
tion of caspase-3 compared to either GTT (0.5%) or HC
(42.5%) alone (Figure 4). Highest induction (79.4%) of
active caspase-3 was observed in LN18 when treated
with combination compounds compared to both 1321N1
and SW1783.
Similar results were obtained for double fluorescence
staining of annexin-V FITC/PI flow cytometry assay. As
shown in Figure 5B(i), the percentage of both early (18.7%)
and late apoptotic cells (32.8%) for GTT +HC treatment
in 1321N1 cells increased significantly compared to GTT
or HC treatment alone. Early apoptosis (25.6%) was
increased in LN18 treated with combined GTT + HC
when compared to GTT or HC monotherapy respectively
(Figure 5B(iii)). However, no significant changes were seen
in the percentage of late apoptosis for LN18 cells treated
with GTT + HC compared to HC alone. In contrast,
SW1783 revealed increased late apoptotic cells (22.7%)
with treatment of combined GTT + HC, while early
apoptotic cells were found to be decreased with combined
GTT+HC treatment (7.1%) compared to GTT alone
(10.8%) (Figure 5B(ii)). Interestingly, the percentage ofwth inhibition of 50% (IC50) on glioma cancer 1321N1,
bination
Tb [μg/ml] HCb [μg/ml] Combination Indexc (CI)
0 75 0.55 ± 0.07
95 0.54 ± 0.03
119 0.73 ± 0.03
nism.
(i) (ii)



















Figure 2 Morphological changes of 1321N1, SW1783 and LN18 cells after treatment. a. Morphological changes of 1321N1 cells after
treatment with (i) vehicle untreated cells (ii) GTT 40 μg/ml, (iii) HC 12 μg/ml, (iv) 40 μg/ml of GTT + 12 μg/ml of HC, (v) scale 100 μm; 40 μg/ml
of GTT + 12 μg/ml of HC; for 24 h. Arrow shows; x. chromatin margination (cresents), y. the collapse of nuclease and vacuolized cytoplasm, and z. cell
shrinkage. b. Morphological changes of SW1783 cells after treatment with (i) vehicle untreated cells (ii) GTT 40 μg/ml, (iii) HC 2 μg/ml, (iv) 40 μg/ml
of GTT + 2 μg/ml of HC, (v) scale 100 μm; 40 μg/ml of GTT + 2 μg/ml of HC; for 24 h. Arrow represents; x. collapse of nuclease, y. volume loss and
chromatin clumping, and z. cell shrinkage. c. Morphological changes of LN18 cells after treatment with (i) vehicle untreated cells (ii) GTT 20 μg/ml, (iii)
HC 29 μg/ml, (iv) 20 μg/ml of GTT + 29 μg/ml of HC, (v) scale 100 μm; 20 μg/ml of GTT + 29 μg/ml of HC; for 24 h. Arrow represents x. volume loss
and chromatin clumping, y. collapse of nuclease, and z. cell shrinkage.
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SW1783 treated with GTT +HC (11.7%), as well as GTT
(9.1%) or HC (9.5%) (Figure 5B(ii)) compared to necrotic
cells in 1321N1 (Figure 5B(i)) and LN18 (Figure 5B(iii))
cells which were below than 5%.The effect of combined GTT + HC on normal cells
Treatment of combined GTT + HC using IC50 doses
obtained from the MTS assay data on normal embry-
onic liver cells (WRL 68) and normal foreskin fibroblast
cells showed no signs of toxicity. Moreover, most of the
Figure 3 Isobologram analysis of GTT and HC antiproliferative effects on glioma cells. Individual IC50 doses for GTT and HC were calculated
and then plotted on the x and y axes. The line connecting these points represents the drug doses of each compound that would induce the same
growth inhibition when used in combination if the interaction between these compounds were additive. The data point on the isobologram
represents the actual doses of combined GTT and HC treatment that results in 50% growth inhibition. Since the data point is positioned well below
the line, a synergistic anti-proliferative effect is indicated.
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cell proliferation of these cells (Figure 6).
Discussion
Recently, there is increased interest in the search for
potential chemopreventive agents for treatment against
various types of cancer particularly as adjuvant therapy
and in the prevention of recurrence. Insights on the mech-
anism of natural bioactives in regulating cell survival
and proliferation are important in the development of
new agents that can be utilized in low toxicity without
the severe side effects accompanying chemotherapy.
The present study provides evidence that both GTT
and HC act as a potent growth inhibitory compound in
human glioma cancer cells. Our study suggests that
LN18 (grade IV) cells were more sensitive to GTT
treatment alone with an IC50 (42 μg/ml) value which is
much lower than grade II 1321N1 (100 μg/ml) and
grade III SW1783 cells (79 μg/ml). As for HC treatment,
1321N1 (grade II) cells were more susceptible to HC
alone with IC50 (75 μg/ml) much lower than grade III
SW1783 (95 μg/ml) and grade IV LN18 cells (119 μg/ml)
(Table 1). Although further studies are required, these
low concentrations maybe achievable in terms of plasma
concentrations suggesting achievable bioavailability of these
natural bioactives. These early findings also suggested
that different grade tumours responded differently to the
bioactives and possibly target different sites of action.
In a number of cell types, GTT or HC were found to
produce an anticancer activity and induce apoptosis.
Tocotrienols has anti-angiogenic properties [7], while
HC was reported to modulate immune responses [11].
Previous investigation have shown that GTT inducesgrowth arrest through several pathways such as through
the suppression of ß-catenin/Tcf signaling in human
colon cancer HT29 cells [21] and has been reported to
modulate a novel pathway through down-regulation of
TGFß2 in prostate cancer [22]. Furthermore, studies by
S Shah, A Gapor and PW Sylvester [23] and S Shah and
PW Sylvester [24] revealed that GTT induced apoptosis
by caspase-8 and caspase-3 but not caspase-9 activation
in neoplastic mammary epithelial cells. HC was shown
to possess antibacterial activity at high concentration of
500 μg/ml and inhibited MCF-7 cell growth at IC50 of
200 μM [25]. Each of the glioma cell lines tested in
this study possess different characteristics. For example,
1321N1 cells contain M2-gland muscarinic receptors [26],
while some of the characteristics of SW1783 cell lines
include the presence of PDGFRA (4q11) amplification,
wild type CDKN2A, PIK3CA (3q26.3) one copy loss
and low-level copy number gain of BIRC5 (17q25) [27].
While LN18 was identified to carry a p53+ mutated gene,
PTEN + wild type, p16- deleted and p14ARF- deleted
gene, besides has been reported to be negative for glial
fibrillary acidic proteins and S-100 proteins [28-30]. Per-
haps, specific characteristics such as different mutations
involved in different grades of glioma cell lines influenced
the choice of route of signaling pathway mediated by GTT
and HC in order to inhibit the proliferation of glioma
cells [31]. This is further supported by evidence which
have shown that tocotrienols mediated its apoptotic
effect through activation of different intracellular signaling
mechanisms in different types of cancer cells [8]. This
may provide an explanation for the different doses of
each bioactives required to inhibit proliferation of the
cancer cells in culture [31].
Figure 4 Detection of apoptosis using flow cytometry after caspase-3 antibody staining. 1321N1, SW1783 and LN18 cells were treated
with combined treatments at IC50 concentrations for 24 h. (A) An example of active caspase-3 detection diagram from 1321N1 cells: viable cells
are in the left quadrant, while the presence of active caspase-3 is shown in right quadrant (P2). (B) Combined compounds caused greater inhibition of
growth of 1321N1, SW1783 and LN18 cells than either agent alone as evidence by the presence of active caspase-3. Each value represents mean ± SD
of three independent experiments. *P < 0.05 compare to control. # P < 0.05 compare to GTT. $P < 0.05 compare to HC.
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regulated in glioma cancer, an improvement in inhibition
of tumor growth could be achieved with combination
therapies that affect several targets and possibly override
different drug resistance [1,32]. This is consistent with
the observation that the effectiveness of anticancer
chemotherapy may be improved when multiple drugs
with complimentary mechanisms of action are used in
combination. Combination therapy optimizes the effective-
ness of each treatment by their complimentary action that
will eventually result in synergistic therapeutic response,
while at the same time reducing toxic adverse side
effects associated with high dose monotherapy [5,15].
Evidence have shown that combined low dose tocotrienol
treatment with specific chemotherapeutic drugs such
as statins [33] and celecoxib [34] showed significantly
enhanced therapeutic response compared to that observed
from individual treatments alone. It is possible that
combination of GTT +HC is more effective than narrowlyfocused therapies as each bioactive are likely to impact
several aspects of tumor progression. Our results further
confirmed and extended the findings from previous
studies where a synergistic anti-proliferative response
were observed in grade II, III and IV human glioma
cell lines after exposure to lower dose combination
treatment with GTT and HC compared to individual
treatment alone (Table 2).
The reduction in cell proliferation and increased apop-
tosis are regarded as one of the key strategies for cancer
prevention. As cell death could be divided into necrosis
or apoptosis, it is essential to determine the mode of cell
death induced by combined GTT+HC treatment. Apop-
tosis is a programmed cell death and unlike necrosis, does
not trigger inflammatory responses [35]. SW1783 cells
were observed to finally progress to secondary necrosis
(Figure 5B(ii)). It should be emphasized that secondary
necrosis differs from normal necrosis. During apoptotic
event in vivo, the presence of macrophage or neighboring
Figure 5 Combined treatments potentiate apoptosis mediated cell death in 1321N1, SW1783 and LN18 cells. (A) Detection of apoptosis
using flow cytometry after annexin V-FITC/propidium iodide (PI) staining. 1321N1, SW1783 and LN18 cells were treated with combined treatments at
IC50 concentrations for 24 h. Viable cells are in the lower left quadrant (Q3), early apoptotic cells are in the lower right quadrant (Q4), late apoptotic
cells are in the upper right quadrant and non-viable necrotic cells are in the upper left quadrant (Q1). (B) Bar graph representing mean values from
three independent experiments for i.1321N1, ii. SW1783 and iii. LN18. *P < 0.05 compare to control early or late apoptosis respectively. # P < 0.05
compare to GTT early or late apoptosis respectively. $P < 0.05 compare to HC early or late apoptosis respectively.
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avoiding lysis. However, due to the absence of phagocytes,
the apoptotic bodies produced in vitro will eventually
swell and lyse [36]. As GTT, HC and their combination
induced cell death follow the sequence of early apoptosis,
late apoptosis and secondary necrosis it is concluded than
the treatment actually induce cell death via apoptotic
rather than necrotic pathway.
Synergism between the GTT and HC bioactives may
be due to the fact that the bioactives acting in concert to
reach different targets of the same signalling pathway,Figure 6 Bar graph of normal foreskin fibroblast and normal liver WR
of toxicity were observed. Data represent the mean ± SD (n = 3).controlling apoptosis, thus accelerating cell death process.
The effectiveness of well-chosen combinations has been
proven by a study on prostate cancer [37] where the
combinations of EGCG, genistein and quercetin trigger
apoptosis in CWR22Rv1 via multiple actions, not through
direct inhibition of the tumor but more precisely, by
suppression or activation of different processes, which
are critical for the tumor’s survival. Consistent with our
in vitro data, sub-effective doses of GTT + HC induce
greater effect in glioma cells compared to GTT or HC
compound alone (Figure 4B and Figure 5B).L68 cells treated with combined GTT + HC after 24 hours. No sign
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in causing cell death, but perhaps, due to the different
mutations in 1321N1, SW1783 and LN18, the modulation
of apoptosis by GTT + HC may be through different
pathways. This was observed in a study by Zhang et al.
[38] where the variation in induction of apoptosis by
combined all-trans retinoic acid (ATRA) and/ or interferon
gamma (IFN-γ) might be attributed to the difference in
PTEN expression in LN18 (PTEN-proficient) and U87MG
(PTEN-deficient) cells. Moreover, gene expression profiling
in estrogen receptor positive, p53 wild-type MCF-7 and
estrogen receptor-negative, p53 mutant MDA-MB 231 cells
treated with tocotrienol-rich fraction of palm oil suggested
different mechanisms in the two cell lines [9].
Vitamin E is a well known antioxidant which scavenges
free radicals and may play a role in preventing oxidative
damage to the prostate epithelium. However, the ability
of GTT, an isomer of vitamin E, in inducing apoptosis
in cancer cells may not necessarily correlate to its
antioxidant characteristics, but GTT may modulate gene-
regulatory functions through mechanisms unrelated to
their antioxidant properties. For example, GTT down-
regulates cyclin D1 and cyclin E levels in several cancer
cell lines. Furthermore, targeting the mevalonate pathway
by tocotrienols for cancer therapy and prevention is
currently under investigation [22].
Evidence suggests that HC elicit cytotoxicity through
mitochondrial failure related to mitochondrial membrane
potential at an early stage and subsequently lipid peroxi-
dation through oxidative stress at a later stage [39]. This
causes release of cytochrome c from mitochondria, cleav-
age of caspase 9, 3 and poly-adenosine diphosphate-ribose
polymerase (PARP) leading to apoptosis. Interestingly,
HC was recently found to induce apoptosis of leukemic
(CML) cell lines expressing mutated Bcr-Abl with imatinib
resistance phenotype [12]. HC also showed scavenging
properties toward H2O2, superoxide and hydroxyl radicals
and is possibly an antioxidant at low concentrations
whereas at higher concentrations, HC induces glutathione
(GSH) depletion, reactive oxygen species (ROS) produc-
tion, cell cycle arrest and apoptosis of oral KB epithelial
cells (cell death mediated by oxidative stress) [10]. A study
by Chen et al. [40] tested the potential cytotoxic effects
of HC in metabolically competent human liver derived
HepG2cells by examining the modulation factors that
may contribute to HC-induced toxicity and apoptotic
effects, and the relationship to oxidative stress [40].
Furthermore, both tocotrienols [41] and HC [11] have
been reported to be capable of crossing the blood–brain
barrier. Therefore, the use of combined GTT +HC is an
attractive approach for cancer chemoprevention in glioma
cancer due to the bioavailability of these bioactives in
the brain. Finally, GTT displays potent anticancer activity
against numerous cancer cells at treatment doses thathave little or no effect on normal cell function and viability
[7], while HC was shown to induce cell death of leukemic
cell lines with minimal toxicity to normal peripheral
blood mononuclear cells [12]. Combined GTT +HC may
be considered as potential therapy for glioma cancer
treatment as it is able to selectively induce apoptosis in
grade II, III and IV cells in this study without affecting
normal embryonic liver cells (WRL 68) and normal fore-
skin fibroblast cells (Figure 6), while most of the treatment
doses of GTT +HC tested increased cell proliferation of
these normal cells.
Overall, synergy effects in pharmacology area are
already known, but their exact mechanisms have yet to
be elucidated. Although tocotrienols have the potential
to be chemotherapeutic or preventive agents in the human
diet and HC has been reported to possess anticancer
activity, their exact mechanisms of action on cell death
and other inhibitory pathways are less known. Future
studies on the elucidation of mechanisms induced by
combined GTT + HC are warranted.
Conclusions
Data from our in vitro studies demonstrated that combined
GTT+HC treatment synergistically induced anticancer
response mediated by apoptosis via caspase-3 in 1321N1,
SW1783 and LN18 than either bioactives alone. Fur-
thermore, different ratios of combined GTT + HC were
needed to achieve the enhanced inhibitory effect against
different grades of glioma cell lines.
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